Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Antigen Specific Adoptive T Cell Therapy for Opportunistic Cytomegalovirus Infection Occurring After Stem Cell Transplant

NCT02982902 is registered in ClinicalTrials.gov with Mari Dallas as lead sponsor.

NCT NCT02982902
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02982902 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Antigen Specific Adoptive T Cell Therapy for Opportunistic Cytomegalovirus Infection Occurring After Stem Cell Transplant
Lead sponsor
Mari Dallas
Phase
Phase 1
Overall status
Recruiting
Start date
May 27, 2020
Completion date
August 31, 2028
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cytomegalovirus infections, hematopoietic stem cell transplant, opportunistic infections